A new antimicrobial peptide designed based on Clostridioides difficile IF1 shows broad-spectrum inhibitory activities against C. difficile and other bacterial strains. https://t.co/7kIGgaGKXp
In @CIDJournal, Pablo Okhuysen, MD, FACP, FIDSA, and colleagues aim to confirm the superiority of ridinilazole over vancomycin on Sustained Clinical Response and recurrent CDI as reported in a Phase II Study.
Read: https://t.co/TM6jlH0gkG
Friday Celebrations! Chenlin Hu, PhD and @GareyKgarey published a review of microscopy methods for C. difficile in Anaerobe! 🔬🦠
Check it out ⬇️⬇️
https://t.co/xlUi9ljaXX
@AnaerobeSociety@UH_Pharmacy
🌟And the publications keep coming!🌟
Check out our labs most recent work on ibezapolstat activity against MDR C. difficile strains ⬇️⬇️
https://t.co/v47gdM43cc
TLDR: IBZ bactericidal activity was similar to the MIC and maintained in wild-type and non-susceptible strains.
🆕️🔥Multicenter cohort study included adults with C. difficile infection @CIDJournal
Vancomycin MIC >2 μg/mL in Clostridioides difficile was associated with decreased odds of 30-day sustained clinical response & lower 14-day initial cure rates #IDXposts https://t.co/ZEgizivUhz
Pleased to share this publication on vaccine potential of Salmonella against C. difficile in a mouse model: a collaboration with Brian Ward and Ph. D. student Kaitlin Winter @MIMM_McGill and my group @inrsciences@infectiopole. Out in Microbiol. Spectrum: https://t.co/Ccz1OWU2fT
Have you seen this new @AmCollegeGastro monograph on microbiome therapeutics?
✅ Essential aspects of methods for analyzing the microbiome
✅ Present and future therapeutics for C. difficile
✅ Non-prescription therapeutics
👉 https://t.co/LGKNgsPW1C
Happy to share the latest preprint from the @StadtmuellerLab - an incredible effort by recent PhD student @Sonya31397350! Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile https://t.co/oRKW4aeKPe
Grat to Jannie and CMAT for this study on bacterial and fungal microbiome interactions in patients colonized or infected with Cdiff. @EurFmt@CMIJournal@SmitsLab
https://t.co/8d2aCbjaeZ
🆕🔥Our study on C. difficile infections among allogeneic HCT recipients in the framework of the Swiss Transplant Cohort Study🇨🇭@BMTjournal@TheEBMT
A short summary 🔽1/5 #IDTwitter https://t.co/fknqY0NNGs